NVCN

Neovasc Inc. (NVCN) | Rumor.io

Neovasc

NVCN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NVCN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 11

Neovasc Inc. (NVCN) has been delisted from the US stock market due to alleged fraud and manipulation.
The company was acquired by Shockwave Medical on April 11, 2023, as announced in a 6-K filing with the SEC.
Neovasc's Reducer device has been reported to have a breakthrough status, with no similar devices from competing companies, except for Gilead's drug "Ranexa".

Generated by AI

Sentiment

Of the messages about NVCN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	60% -16.92
Bearish	—	—	—	40% +16.92

Bullish· Jan 17

$NVCN is being acquired by $SWAV at $27.25 per share, a significant premium that could lead to a substantial increase in value.
The acquisition of $NVCN by $SWAV is a positive development for the company, as it brings in a larger partner with the resources to help it grow and expand its market.
The deal is seen as a great opportunity for $NVCN stakeholders, who will benefit from the acquisition and potentially see a significant return on their investment.

Bearish· Jan 17

The acquisition of $NVCN by Shockwave Medical is seen as a giveaway, with the company being sold for a relatively low price.
Many investors have expressed regret over holding onto $NVCN, with some mentioning that they were burned by the company's reserve splits and others feeling misled by bearish predictions.
The company's financial projections are called into question, with some pointing out that the projected revenue is not reflective of the current market value of the company.

Generated by AI

Topics

Of the messages about NVCN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· May 9

Neovasc Inc. (NVCN) reported a loss of $0.20, missing the consensus estimate by $0.14.
The company beat revenue expectations, with Reducer revenue increasing 72% to $585,793 for the quarter.
Analysts were divided on the earnings report, with some viewing it as a beat and others as a miss due to the EPS miss.

Analysts· Mar 29

Neovasc Inc. (NVCN) has received a price target of $2.00 from Leerink Swann, with an outperform rating.
Canaccord Genuity has cut its price target for NVCN to $0.50, while maintaining a buy rating.
The consensus price target for NVCN is $2.76, with a consensus rating of "hold".

Announcements· Jan 17

Neovasc Inc. (NVCN) has entered into an agreement to be acquired by Shockwave Medical (SWAV) for approximately $100 million, with an upfront cash payment of $27.25 per share and a potential deferred payment of up to $12 per share.
The acquisition is valued at $100 million, with Neovasc shareholders receiving a premium of 27% and 68% to the closing price and 30-day VWAP, respectively, of Neovasc's common shares on the Nasdaq Capital Market on January 13, 2023.
The deal is expected to close, with Neovasc shareholders receiving a non-tradable contingent value right (CVR) entitling them to receive up to an additional $12 per share in cash if certain regulatory milestones are achieved.

Controversies· Apr 17

Neovasc Inc. (NVCN) has resolved its last remaining active litigation with Edwards over CardiAQ patents, with no monetary damages awarded.
The settlement was reached after years of litigation, which was a major factor in NVCN's stock decline in the past.
The resolution of the litigation has led to a 2% increase in NVCN's shares and a settlement of the patent arbitration dispute with Edwards.

Technical Analysis· Feb 10

The post discusses Neovasc Inc. (NVCN) stock as having a big trend ahead and mentions a potential breakout.
The post highlights NVCN stock chart technical analysis, including a potential continuation of the uptrend and a buy signal on the 5min supertrend.
The post suggests that NVCN needs to stay above $1.90 for bullish follow-through, with a potential breakout above $2.05 and a resistance level at $3.50.

Generated by AI

Community

Of the messages about NVCN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	13.64%
Newcomers	—	—	—	86.36%

Regulars· Jan 17

Neovasc Inc. ($NVCN) has agreed to be acquired by Shockwave Medical in a deal valued at approximately $100M, with $27.25 per share in cash upfront and $12 in contingent value rights.
The acquisition is expected to be completed, with Neovasc's share price increasing by over 30% and reaching a new 52-week high.
Neovasc's preliminary Q4 revenue and FY23 revenue guidance have been reported, with preliminary Q4 revenue at $143-144M and initial FY23 revenue at $660-680M.

Newcomers· Jan 17

The acquisition of Neovasc Inc. by Shockwave Medical is for $27.25 per share, with a total value of around $100 million.
The deal has been announced, and it is expected to be completed soon, with the exact terms and details still being finalized.
The acquisition is seen as a strategic move by Shockwave Medical to expand its product portfolio and increase its presence in the medical device market.

Generated by AI

Also Discussed

Investors talking about NVCN also mention

#	Name	Attention
1	Boston Scientific Corp.BSX	0.03%-0.02
2	Top Ships Inc.TOPS	0%+0
3	Jaguar Health, Inc.JAGX	0.02%-0.02
4	InspireMD, Inc.NSPR	0%new
5	My Size, Inc.MYSZ	0%new
6	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
7	Origin Agritech Ltd.SEED	0%new
8	AB Corporate Bond ETFEYEG	0%0
9	RHE - Regional Health Properties, Inc.	——
10	Integrated Media Technology LimitedIMTE	0%0

Neovasc Inc.

Location

Social

What share of all stock conversation is about NVCN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 11

Neovasc Inc. (NVCN) has been delisted from the US stock market due to alleged fraud and manipulation.
The company was acquired by Shockwave Medical on April 11, 2023, as announced in a 6-K filing with the SEC.
Neovasc's Reducer device has been reported to have a breakthrough status, with no similar devices from competing companies, except for Gilead's drug "Ranexa".

Generated by AI

Sentiment

Of the messages about NVCN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	60% -16.92
Bearish	—	—	—	40% +16.92

Bullish· Jan 17

$NVCN is being acquired by $SWAV at $27.25 per share, a significant premium that could lead to a substantial increase in value.
The acquisition of $NVCN by $SWAV is a positive development for the company, as it brings in a larger partner with the resources to help it grow and expand its market.
The deal is seen as a great opportunity for $NVCN stakeholders, who will benefit from the acquisition and potentially see a significant return on their investment.

Bearish· Jan 17

The acquisition of $NVCN by Shockwave Medical is seen as a giveaway, with the company being sold for a relatively low price.
Many investors have expressed regret over holding onto $NVCN, with some mentioning that they were burned by the company's reserve splits and others feeling misled by bearish predictions.
The company's financial projections are called into question, with some pointing out that the projected revenue is not reflective of the current market value of the company.

Generated by AI

Topics

Of the messages about NVCN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· May 9

Neovasc Inc. (NVCN) reported a loss of $0.20, missing the consensus estimate by $0.14.
The company beat revenue expectations, with Reducer revenue increasing 72% to $585,793 for the quarter.
Analysts were divided on the earnings report, with some viewing it as a beat and others as a miss due to the EPS miss.

Analysts· Mar 29

Neovasc Inc. (NVCN) has received a price target of $2.00 from Leerink Swann, with an outperform rating.
Canaccord Genuity has cut its price target for NVCN to $0.50, while maintaining a buy rating.
The consensus price target for NVCN is $2.76, with a consensus rating of "hold".

Announcements· Jan 17

Neovasc Inc. (NVCN) has entered into an agreement to be acquired by Shockwave Medical (SWAV) for approximately $100 million, with an upfront cash payment of $27.25 per share and a potential deferred payment of up to $12 per share.
The acquisition is valued at $100 million, with Neovasc shareholders receiving a premium of 27% and 68% to the closing price and 30-day VWAP, respectively, of Neovasc's common shares on the Nasdaq Capital Market on January 13, 2023.
The deal is expected to close, with Neovasc shareholders receiving a non-tradable contingent value right (CVR) entitling them to receive up to an additional $12 per share in cash if certain regulatory milestones are achieved.

Controversies· Apr 17

Neovasc Inc. (NVCN) has resolved its last remaining active litigation with Edwards over CardiAQ patents, with no monetary damages awarded.
The settlement was reached after years of litigation, which was a major factor in NVCN's stock decline in the past.
The resolution of the litigation has led to a 2% increase in NVCN's shares and a settlement of the patent arbitration dispute with Edwards.

Technical Analysis· Feb 10

The post discusses Neovasc Inc. (NVCN) stock as having a big trend ahead and mentions a potential breakout.
The post highlights NVCN stock chart technical analysis, including a potential continuation of the uptrend and a buy signal on the 5min supertrend.
The post suggests that NVCN needs to stay above $1.90 for bullish follow-through, with a potential breakout above $2.05 and a resistance level at $3.50.

Generated by AI

Community

Of the messages about NVCN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	13.64%
Newcomers	—	—	—	86.36%

Regulars· Jan 17

Neovasc Inc. ($NVCN) has agreed to be acquired by Shockwave Medical in a deal valued at approximately $100M, with $27.25 per share in cash upfront and $12 in contingent value rights.
The acquisition is expected to be completed, with Neovasc's share price increasing by over 30% and reaching a new 52-week high.
Neovasc's preliminary Q4 revenue and FY23 revenue guidance have been reported, with preliminary Q4 revenue at $143-144M and initial FY23 revenue at $660-680M.

Newcomers· Jan 17

The acquisition of Neovasc Inc. by Shockwave Medical is for $27.25 per share, with a total value of around $100 million.
The deal has been announced, and it is expected to be completed soon, with the exact terms and details still being finalized.
The acquisition is seen as a strategic move by Shockwave Medical to expand its product portfolio and increase its presence in the medical device market.

Generated by AI

Neovasc

Social

Apr 11

Sentiment

Bullish· Jan 17

Bearish· Jan 17

Topics

Earnings· May 9

Analysts· Mar 29

Announcements· Jan 17

Controversies· Apr 17

Technical Analysis· Feb 10

Community

Regulars· Jan 17

Newcomers· Jan 17

Also Discussed

Neovasc Inc.

Company Information

Location

Also Discussed

Social

Apr 11

Sentiment

Bullish· Jan 17

Bearish· Jan 17

Topics

Earnings· May 9

Analysts· Mar 29

Announcements· Jan 17

Controversies· Apr 17

Technical Analysis· Feb 10

Community

Regulars· Jan 17

Newcomers· Jan 17